TRCT
UNCY icon

Tower Research Capital (TRC)’s Unicycive Therapeutics UNCY Stock Holding History

Tower Research Capital (TRC)’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,920
Closed -$11.1K – 5581
2025
Q4 		$11.1K Buy
+1,920
New +$10.3K ﹤0.01% 3656
2025
Q1 		– Sell
-1,089
Closed -$8.64K – 5808
2024
Q4 		$8.64K Sell
1,089
-1,189
-52% -$6.58K ﹤0.01% 3979
2024
Q3 		$9.29K Buy
2,278
+429
+23% +$1.72K ﹤0.01% 3881
2024
Q2 		$9.26K Buy
1,849
+1,081
+141% +$10.6K ﹤0.01% 4272
2024
Q1 		$10.6K Buy
768
+92
+14% +$1.11K ﹤0.01% 3677
2023
Q4 		$5.87K Buy
676
+369
+120% +$2.41K ﹤0.01% 4796
2023
Q3 		$2.64K Buy
307
+100
+48% +$937 ﹤0.01% 5126
2023
Q2 		$2.65K Sell
207
-135
-39% -$2.11K ﹤0.01% 5172
2023
Q1 		$7K Sell
342
-158
-32% -$1.57K ﹤0.01% 4778
2022
Q4 		$3K Sell
500
-18
-3% -$122 ﹤0.01% 5244
2022
Q3 		$3K Buy
518
+1
+0.2% +$7 ﹤0.01% 5433
2022
Q2 		$4K Buy
517
+133
+35% +$1.27K ﹤0.01% 5260
2022
Q1 		$5K Buy
+384
New +$5.62K ﹤0.01% 5108

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s UNCY Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Unicycive Therapeutics (UNCY) in Q1 2026, closing a stake of 1,920 shares — an estimated $11.1K sold.

Tower Research Capital (TRC) first reported a position in UNCY in Q1 2022 and held it in 13 quarters. The position peaked at $11.1K in Q4 2025. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Unicycive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,920 Unicycive Therapeutics shares in Q1 2026, an estimated $11.1K.
  • Tower Research Capital (TRC) first reported a position in Unicycive Therapeutics in Q1 2022 and held it in 13 quarters.
  • Tower Research Capital (TRC)'s Unicycive Therapeutics position peaked at $11.1K in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.